Holen Sie sich die Stockscreener-App
9.936
1.53%
0.126
Schlusskurs vom Vortag:
$9.81
Offen:
$9.82
24-Stunden-Volumen:
9,079
Relative Volume:
0.01
Marktkapitalisierung:
$501.33M
Einnahmen:
$85.21M
Nettoeinkommen (Verlust:
$-140.11M
KGV:
-3.9513
EPS:
-2.5146
Netto-Cashflow:
$-109.62M
1W Leistung:
+0.20%
1M Leistung:
+19.57%
6M Leistung:
+3.00%
1J Leistung:
+278.71%
1-Tages-Spanne:
$9.82
$9.8201
1-Wochen-Bereich:
$9.49
$10.88
52-Wochen-Spanne:
$2.56
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Firmenname
4 D Molecular Therapeutics Inc
Sektor
Branche
Telefon
(510) 505-2680
Adresse
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
9.8201 | 500.82M | 85.21M | -140.11M | -109.62M | -2.5146 |
VRTX
Vertex Pharmaceuticals Inc
|
435.03 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.95 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.99 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.52 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-11-07 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Underweight |
| 2024-09-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Eingeleitet | Barclays | Overweight |
| 2024-02-07 | Fortgesetzt | Goldman | Buy |
| 2023-10-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-12 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Eingeleitet | Jefferies | Buy |
| 2022-01-04 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-05 | Eingeleitet | Goldman | Neutral |
Alle ansehen
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
Layoff Watch: What is the Moat Score of 4D Molecular Therapeutics Inc2026 Short Interest & AI Based Buy and Sell Signals - baoquankhu1.vn
Janus Henderson (NASDAQ: FDMT) holds 5.25M shares, 10.3% stake in 4D Molecular - Stock Titan
Investment Analysts’ Recent Ratings Changes for 4D Molecular Therapeutics (FDMT) - Defense World
JPMorgan Chase & Co. Has $4.46 Million Stock Holdings in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Buy Rating from Jefferies Financial Group - Defense World
4D Molecular Therapeutics Inc (FDMT) Stock Price Quote Today & Current Price Chart - Capital.com
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role - TipRanks
FDMT SEC Filings4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Trade 4D Molecular Therapeutics IncFDMT CFD - Capital.com
4D Molecular Therapeutics appoints Kristian Humer as Principal Accounting Officer - TradingView
4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer - Stock Titan
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at Jefferies Financial Group - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $32.71 Consensus Target Price from Analysts - Defense World
4D Molecular Therapeutics, Inc. Announces Executive Changes, Effective March 25, 2026 - marketscreener.com
4D Molecular Therapeutics Inc : Jefferies Ass - Moomoo
CEO at 4D Molecular (NASDAQ: FDMT) awarded 750K stock options - Stock Titan
4D Molecular (NASDAQ: FDMT) awards 217,000 stock options to CLO - stocktitan.net
4D Molecular (NASDAQ: FDMT) awards 219,000 stock options to company officer - Stock Titan
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Vanguard amendment shows 0 shares of 4D Molecular (NASDAQ: FDMT) - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% HigherHere's Why - MarketBeat
VP Gupta of 4d molecular sold $3357 in FDMT stock - Investing.com UK
4D Molecular (NASDAQ: FDMT) VP uses share sale to cover taxes - Stock Titan
Research Analysts Issue Forecasts for FDMT FY2030 Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
4D Molecular Therapeutics (NASDAQ:FDMT) Raised to "Hold" at Wall Street Zen - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Raised to “Hold” at Wall Street Zen - Defense World
4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald - The Globe and Mail
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
4D Molecular Therapeutics’ (FDMT) Buy Rating Reaffirmed at Chardan Capital - Defense World
Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies - TipRanks
4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative - simplywall.st
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank Of Canada - MarketBeat
4D Molecular Therapeutics (FDMT): RBC Capital Raises Price Targe - GuruFocus
Chardan Capital Reiterates "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat
RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk - marketscreener.com
4D Molecular Therapeutics (FDMT) Reports 2025 Financial Results, Advances 4D-150 Wet AMD Phase 3 Trials, and Extends Cash Runway Into 2028 - Minichart
4D Molecular Therapeutics, Inc. 2025 Annual Report: Innovative AAV Gene Therapy Pipeline for Retinal and Pulmonary Diseases - Minichart
4D Molecular Therapeutics, Inc. (FDMT) Q4 Results Surpass Forecasts for Earnings and Revenue - Bitget
4D Molecular Therapeutics, Inc. (FDMT) Q4 earnings and revenues beat estimates - MSN
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
4D Molecular Therapeutics : 4DMT Corporate Presentation – March 2026 (dfceb5) - marketscreener.com
4D Molecular Therapeutics 10-K: $85.2M collaboration revenue; improved net loss $140.1M - TradingView
4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results, Beats Estimates By $0.96 EPS - MarketBeat
4D Molecular Therapeutics (FDMT) details retina and lung gene therapy pipeline in 10-K - Stock Titan
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Therapeutics (NASDAQ: FDMT) posts 2025 results, inks Otsuka deal, extends cash runway - Stock Titan
Finanzdaten der 4 D Molecular Therapeutics Inc-Aktie (FDMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.62%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):